Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
暂无分享,去创建一个
T. Ittel | R. Naumann | K. Höffken | R. Rohrberg | A. Neubauer | M. Herold | M. Assmann | A. Franke | M. Freund | U. von Grünhagen | C. Klinkenstein | W. Knauf | G. Dölken | U. Mey | E. Kettner | A. Haas | S. Srock | S. Neser | U. Haak | K. H. Al-Ali | G. Dölken
[1] R. Marcus,et al. MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL). , 2006 .
[2] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[3] R. Gascoyne,et al. Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. , 2005 .
[4] W. Hiddemann,et al. Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) , 2005 .
[5] R. Gressin,et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. , 2005, Blood.
[6] T. Lister,et al. The clinical course of follicular lymphoma. , 2005, Best practice & research. Clinical haematology.
[7] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[8] A. Chott,et al. Effective Treatment of Indolent Non-Hodgkin’s Lymphomas with Mitoxantrone, Chlorambucil and Prednisone , 2005, Oncology Research and Treatment.
[9] E. Estey,et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. , 2004, Blood.
[10] 渡邉 隆. What's going on 造血器腫瘍 Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. J Clin Oncol. 2004;22:4659-64. PMID:15483 , 2005 .
[11] M. Czuczman,et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] E. Kimby,et al. Chimeric Anti-CD20 Monoclonal Antibody (Rituximab;Mabthera) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Final Analysis of a Phase III Randomized Intergroup Clinical Trial. , 2004 .
[13] G. Salles,et al. Rituximab Added αIFN+CHVP Improves the Outcome of Follicular Lymphoma Patients with a High Tumor Burden: to First Analysis of the GELA-GOELAMS FL-2000 Randomized Trial in 359 Patients. , 2004 .
[14] Hervé Watier,et al. From the bench to the bedside: ways to improve rituximab efficacy. , 2004, Blood.
[15] M. Ghielmini,et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. , 2004, Blood.
[16] K. Landys. Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma , 1988, Investigational New Drugs.
[17] W. Scheithauer,et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] M. Sydes,et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T. Lister. High-dose therapy for follicular lymphoma revisited: not if, but when? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Maloney,et al. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. , 2002, Blood.
[21] S. Boehrer,et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. , 2002, Haematologica.
[22] A. López-Guillermo,et al. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] L. Gordon,et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[27] A. Demidem,et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. , 1997, Cancer biotherapy & radiopharmaceuticals.
[28] W Hiddemann,et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. , 1996, Leukemia.
[29] A. Avilés,et al. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. , 1996, Leukemia & lymphoma.
[30] T. Lister,et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] P. Chinn,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.
[32] W. Hiddemann,et al. Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study. , 1990, Seminars in oncology.
[33] M. Greene,et al. Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents. , 1987, Hematologic pathology.